Immunotherapy in Lung Cancer Articles | Page 3

Emerging Data Show Promise With Immunotherapy Combos in NSCLC
Jyoti D. Patel, MD, discusses ongoing research investigating immunotherapy in combination with chemotherapy for patients with NSCLC.
Standard Biopsies Retain Significant Role in Lung Cancer Care
Philip D. Bonomi, MD, discusses some of the known biomarkers in non-small cell lung cancer (NSCLC), the utilization of PD-L1, and other testing modalities.
Atezolizumab Approved in Europe for Lung, Bladder Cancer
The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.
Nab-Paclitaxel Alone and With Durvalumab Shows Promise in NSCLC
Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.
Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy
A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non-small cell lung cancer treated with a checkpoint inhibitor.
Optimizing Immunotherapy Remains a Challenge in NSCLC
David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.
Expert Explains Approaches in Non-Driver NSCLC
Lyudmila A. Bazhenova, MD, discusses the non-driver NSCLC population, the treatment strategies available for them, and challenges physicians continue to face with this subgroup of patients.
ASCO Updates Treatment Guidelines for Advanced NSCLC
ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer.
RT Options Evolving in Oligometastatic Lung Cancer Landscape and Beyond
Billy W. Loo Jr, MD, PhD, discusses the advancements in radiation therapy options for patients with lung cancer, how SABR has improved outcomes for patients, and the intriguing combinations being explored with RT and immunotherapy. 
Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLC
Joel Neal, MD, discusses the latest therapeutic changes to the ALK-positive NSCLC armamentarium.
Publication Bottom Border
Border Publication